CD44 and sarcoma: Further analysis of differentially methylated regions between tumors within the novel group and CIC-rearranged sarcoma showed aberrant methylation patterns, including promoter region hypomethylation amongst others of CD44, EMP3, and VIM in these tumors (Fig. 1c).